An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules-Reference-Cited by-同舟云学术

An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules

Published:2018-10-15 Issue:10 Volume:13 Page:e0205491
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Harper Jane,Adams Katherine J.,Bossi Giovanna,Wright Debbie E.,Stacey Andrea R.,Bedke Nicole,Martinez-Hague Ruth,Blat Dan,Humbert Laure,Buchanan Hazel,Le Provost Gabrielle S.,Donnellan Zoe,Carreira Ricardo J.^ORCID,Paston Samantha J.,Weigand Luise U.,Canestraro Martina,Sanderson Joseph P.,Botta Gordon-Smith Sophie^ORCID,Lowe Kate L.,Rygiel Karolina A.,Powlesland Alex S.,Vuidepot Annelise,Hassan Namir J.,Cameron Brian J.,Jakobsen Bent K.,Dukes Joseph

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference41 articles.

1. Cancer immunotherapy: the beginning of the end of cancer?;S Farkona;BMC medicine,2016

2. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps;P Sharma;Nature reviews Cancer,2011

3. The blockade of immune checkpoints in cancer immunotherapy;DM Pardoll;Nature reviews Cancer,2012

4. Improved survival with ipilimumab in patients with metastatic melanoma;FS Hodi;The New England journal of medicine,2010

5. Adoptive cell transfer: a clinical path to effective cancer immunotherapy;SA Rosenberg;Nature reviews Cancer,2008

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineered T cells for Colorectal Cancer;Immunotherapy;2024-09-04

2. Expanding horizons in cancer therapy by immunoconjugates targeting tumor microenvironments;Critical Reviews in Oncology/Hematology;2024-09

3. Tebentafusp Induces a T-Cell–Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action;Journal of Investigative Dermatology;2024-07

4. Roles and mechanisms of aberrant alternative splicing in melanoma — implications for targeted therapy and immunotherapy resistance;Cancer Cell International;2024-03-10

5. Uveal melanoma: Recent advances in immunotherapy;World Journal of Clinical Oncology;2024-01-24